Javier Szwarcberg
Chief Executive Officer chez SPRUCE BIOSCIENCES, INC.
Fortune : 84 354 $ au 31/03/2024
Profil
Javier Szwarcberg is currently the Chief Executive Officer & Director at Spruce Biosciences, Inc. Prior to this, he worked as the VP, Head-Product & Portfolio Management at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Plc from 2016 to 2017.
He holds a doctorate degree from Universidad de Buenos Aires and a graduate degree from Harvard T.H.
Chan School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC.
0,26% | 14/03/2024 | 107 321 ( 0,26% ) | 84 354 $ | 31/03/2024 |
Postes actifs de Javier Szwarcberg
| Sociétés | Poste | Début |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Chief Executive Officer | 03/01/2022 |
Anciens postes connus de Javier Szwarcberg
| Sociétés | Poste | Fin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/02/2020 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01/10/2017 |
Formation de Javier Szwarcberg
| Universidad de Buenos Aires | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
